Hydroxychloroquine reduces cardiovascular morbidity risk in people with rheumatoid arthritis

Hydroxychloroquine (Plaquenil®), especially at the higher standard dose of 400 mg per day, independently decreases the risk of cardiovascular morbidity in people with rheumatoid arthritis, according to new research. Accelerated atherosclerosis and cardiovascular disease are two chief causes of mortality associated with RA. The drug has anti-inflammatory properties, and recent data show that it may have additional beneficial effects on cardiovascular risk factors by lowering LDL cholesterol levels.

Leave a Reply

Your email address will not be published. Required fields are marked *